Related Experiment Video

Updated: Aug 9, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Summary of randomized trials of angiotensin converting enzyme inhibitors

S Yusuf1, E Lonn, J Bosch

  • 1Division of Cardiology, McMaster University and The Hamilton Health Sciences Corporation Research Centre, Ontario, Canada.

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|July 28, 1999
PubMed

Insights

Angiotensin converting enzyme (ACE) inhibitors significantly lower risks of death and heart failure in patients with left ventricular dysfunction. These drugs also reduce vascular events and kidney disease progression in hypertensive diabetics.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Heart failure and left ventricular dysfunction increase mortality and morbidity.
  • Acute myocardial infarction carries a high risk of mortality.
  • Hypertension and diabetes are major risk factors for vascular events and renal disease progression.

Purpose of the Study:

  • To summarize the established benefits of Angiotensin Converting Enzyme (ACE) inhibitors.
  • To highlight their efficacy in reducing mortality and major vascular events.
  • To discuss ongoing research into their role in normotensive patients.

Main Methods:

  • Review of clinical trial data and established medical literature.
  • Analysis of outcomes in patients with heart failure, myocardial infarction, hypertension, and diabetes.
  • Examination of comparative effectiveness against placebo and calcium channel blockers.

Main Results:

  • ACE inhibitors reduce death, heart failure worsening, and recurrent infarction in patients with left ventricular dysfunction.
  • They decrease mortality during the acute phase of myocardial infarction.
  • ACE inhibitors show benefits in reducing vascular events and slowing renal disease progression in hypertensive diabetics compared to placebo and calcium channel blockers.

Conclusions:

  • ACE inhibitors are crucial in managing heart failure and post-myocardial infarction patients.
  • They offer significant advantages in patients with hypertension and diabetes, impacting vascular and renal health.
  • Ongoing trials are exploring the broader application of ACE inhibitors in cardiovascular and cerebrovascular disease prevention.

More Related Videos

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials08:36

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials

Published on: April 19, 2024

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...